Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Bluebird bio, Inc.    BLUE

BLUEBIRD BIO, INC.

(BLUE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

Bluebird: 3Q Earnings Snapshot

11/04/2020 | 05:27pm EST

CAMBRIDGE, Mass. (AP) _ Bluebird Bio Inc. (BLUE) on Wednesday reported a loss of $194.7 million in its third quarter.

On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $2.94.

The results topped Wall Street expectations. The average estimate of 12 analysts surveyed by Zacks Investment Research was for a loss of $3.07 per share.

The biotechnology company posted revenue of $19.3 million in the period, which did not meet Street forecasts. Nine analysts surveyed by Zacks expected $26 million.

Bluebird shares have dropped 33% since the beginning of the year. In the final minutes of trading on Wednesday, shares hit $58.55, a decrease of 29% in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on BLUE at https://www.zacks.com/ap/BLUE

Copyright by Automated Insights, Inc. All rights reserved., source Associated Press News

All news about BLUEBIRD BIO, INC.
01/11BLUEBIRD BIO : Insiders at Bluebird Bio (BLUE) Make Significant Stock Sales Exte..
MT
01/11BLUEBIRD BIO, INC. : Results of Operations and Financial Condition, Change in Di..
AQ
01/11BLUEBIRD BIO : to spin off cancer drugs unit to focus on genetic diseases
RE
01/11BLUEBIRD BIO : to Separate Oncology Business into Independent Company
BU
01/11BLUEBIRD BIO : to spin off cancer drugs unit - WSJ
RE
01/08INSIDER TRENDS : Insider Adds to Selling Trend at Bluebird Bio
MT
01/08INSIDER TRENDS : Insider Continues 90-Day Selling Trend at Bluebird Bio
MT
01/08INSIDER TRENDS : 90-Day Insider Selling Trend Prolonged at Bluebird Bio
MT
01/08INSIDER TRENDS : Bluebird Bio Insider Continues 90-Day Selling Trend
MT
2020BLUEBIRD BIO, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal ..
AQ
More news
Financials (USD)
Sales 2020 260 M - -
Net income 2020 -587 M - -
Net cash 2020 1 235 M - -
P/E ratio 2020 -5,06x
Yield 2020 -
Capitalization 3 286 M 3 286 M -
EV / Sales 2020 7,88x
EV / Sales 2021 17,4x
Nbr of Employees 1 171
Free-Float 99,5%
Chart BLUEBIRD BIO, INC.
Duration : Period :
bluebird bio, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BLUEBIRD BIO, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 79,26 $
Last Close Price 49,51 $
Spread / Highest target 195%
Spread / Average Target 60,1%
Spread / Lowest Target -3,05%
EPS Revisions
Managers and Directors
NameTitle
Nick Leschly President, Chief Executive Officer & Director
Daniel S. Lynch Chairman
Jason F. Cole Chief Operating & Legal Officer
William Denise Baird Chief Financial Officer
David M. Davidson Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BLUEBIRD BIO, INC.14.42%3 286
GILEAD SCIENCES, INC.15.12%84 074
VERTEX PHARMACEUTICALS-1.87%60 305
REGENERON PHARMACEUTICALS10.51%56 349
WUXI APPTEC CO., LTD.6.43%53 987
BEIGENE, LTD.38.04%32 523